Cell Therapy & Gene Editing

Advances in our ability to read, write, and edit DNA are transforming medicine. Cell therapies are well positioned to benefit from these advances, but tumor microenvironment resistance, off-target effects and safety, and cell persistence and durability present challenges to developing therapies.

Ginkgo offers capabilities to support a breadth of cell-based therapies: autologous, allogeneic, iPSC-derived, and more. Our interdisciplinary team excels at designing and screening complex libraries for a range of applications, with licensable assets already discovered for CAR designs and synthetic cytokine receptors. Our complementary offerings in mRNA therapeutics can address challenges for in vivo therapies with viral and nonviral delivery.

Systematic discovery of novel CAR designs that drive more favorable T cell phenotypes against tumors has been onerous due to technical constraints in library design and high-throughput screening. Ginkgo created a 10,000-member CAR library composed of different combinations of immune cell signaling components and established a pooled screen platform to discover optimized CAR designs in primary T and NK cells. The platform is extendable to different cell types, binders and can even be used for in vivo screens. In large scale arrayed validated studies, our pooled screen hits have shown enhanced functional properties. Multiple new designs are available for evaluation by our partners.